<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02276027</url>
  </required_header>
  <id_info>
    <org_study_id>CINC280X2205</org_study_id>
    <nct_id>NCT02276027</nct_id>
  </id_info>
  <brief_title>A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer</brief_title>
  <official_title>A Phase II, Open Label, Multiple Arm Study of Single Agent AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the anti-tumor activity of single agent BYL719, INC280, LDK378 and MEK162
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 20, 2015</start_date>
  <completion_date type="Anticipated">August 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>from the date of treatment until disease progression, up to 1 year</time_frame>
    <description>ORR (Overall response rate ) of non-small cell lung cancer (NSCLC) patients. Overall response rate is the proportion of patients with a best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival of NSCLC patients</measure>
    <time_frame>from the date of treatment until death, up to 2 year</time_frame>
    <description>Overall survival (OS) of non-small cell lung cancer (NSCLC) patients. OS is defined as the time from date of randomization/start of treatment to date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival of NSCLC patients</measure>
    <time_frame>from the date of treatment until disease progression, up to 1 year</time_frame>
    <description>Progression-free survival (PFS) of non-small cell lung cancer (NSCLC) patients. PFS is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause according to RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate of NSCLC patients</measure>
    <time_frame>from the date of treatment until disease progression, up to 1 year</time_frame>
    <description>Disease control rate (DCR) of non-small cell lung cancer (NSCLC) patients treated with first or second line therapies. DCR is the proportion of patients with a best overall response of CR or PR or SD according to RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall response of NSCLC patients</measure>
    <time_frame>from the date of treatment until disease progression, up to 1 year</time_frame>
    <description>Duration of overall response (CR or PR) of non-small cell lung cancer (NSCLC) patients. For patients with a CR or PR (which may have to be confirmed the start date is the date of first documented response (CR or PR) and the end date and censoring is defined the same as that for time to progression according to RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency/severity of adverse events (AEs)</measure>
    <time_frame>30 days post treatment</time_frame>
    <description>As a measure of safety and tolerability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics profile of BYL719</measure>
    <time_frame>Day 1, Day 2, Day 15 and Day 16 of cycle 1; Day 1 of Cycle 2 and Cycle3, 1 cycle is 28 days</time_frame>
    <description>Pharmacokinetics parameters including but not limited to area under the curve (AUC0-t), Maximum plasma concentration after a single dose (Cmax), Peak plasma concentration (Tmax), Median terminal elimination half-life (T1/2), The median accumulation ratio (Racc), Clearance (CL/F) and volume of distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics profile of INC280</measure>
    <time_frame>Day 15 and Day 16 of cycle 1; Day 1 of Cycle 2 and Cycle3, 1 cycle is 28 days</time_frame>
    <description>Pharmacokinetics parameters including but not limited to area under the curve (AUC0-t), Maximum plasma concentration after a single dose (Cmax), Peak plasma concentration (Tmax), Median terminal elimination half-life (T1/2), The median accumulation ratio (Racc), Clearance (CL/F) and volume of distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics profile of LDK378</measure>
    <time_frame>Day 15 and Day 16 of cycle 1; Day 1 of Cycle 2 and Cycle3, 1 cycle is 28 days</time_frame>
    <description>Pharmacokinetics parameters including but not limited to area under the curve (AUC0-t), Maximum plasma concentration after a single dose (Cmax), Peak plasma concentration (Tmax), Median terminal elimination half-life (T1/2), The median accumulation ratio (Racc), Clearance (CL/F) and volume of distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics profile of MEK162</measure>
    <time_frame>Day 15 and Day 16 of cycle 1; Day 1 of Cycle 2 and Cycle3, 1 cycle is 28 days</time_frame>
    <description>Pharmacokinetics parameters including but not limited to area under the curve (AUC0-t), Maximum plasma concentration after a single dose (Cmax), Peak plasma concentration (Tmax), Median terminal elimination half-life (T1/2), The median accumulation ratio (Racc), Clearance (CL/F) and volume of distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency/severity of serious adverse events (SAEs)</measure>
    <time_frame>30 days post treatment</time_frame>
    <description>As a measure of safety and tolerability.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>BYL719</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 NSCLC patients. Patient's tumor must have molecular alteration of the PIK3CA gene.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INC280</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 NSCLC patients. Patient's tumor must have molecular alteration of the c-MET gene.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDK378</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 NSCLC patients.Patient's tumor must have ALK or ROS1 gene rearrangement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEK162</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 NSCLC patients. Patient's tumor must have KRAS, NRAS or BRAF mutation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BYL719</intervention_name>
    <description>BYL719 will be dosed as 350 mg once daily. On the first day of each cycle, patient will receive a prescription of adequate drug supply for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take BYL719 exactly as prescribed.</description>
    <arm_group_label>BYL719</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INC280</intervention_name>
    <description>INC280 will be dosed as 600 mg (tablet) or 400mg(Capsule) twice daily. On the first day of each cycle, patient will receive a prescription of adequate drug supply for self-administration at home. The investigator must emphasize compliance and will instruct the patient to takeINC280 exactly as prescribed.</description>
    <arm_group_label>INC280</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDK378</intervention_name>
    <description>LDK378 will be dosed as 750 mg once daily. On the first day of each cycle, patient will receive a prescription of adequate drug supply for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take LDK378 exactly as prescribed.</description>
    <arm_group_label>LDK378</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEK162</intervention_name>
    <description>MEK162 will be dosed as 45 mg twice daily. On the first day of each cycle, patient will receive a prescription of adequate drug supply for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take MEK162 exactly as prescribed.</description>
    <arm_group_label>MEK162</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced (stage IIIB or stage IV) NSCLC

          -  Must have specific molecular alterations

        Exclusion Criteria:

          -  Symptomatic central nervous system (CNS) metastases which are neurologically unstable
             or requiring increasing doses of steroids within the 4 weeks prior to study entry to
             control their CNS disease

          -  Radiation therapy within ≤ 4 weeks prior to study entry, with the exception of limited
             field palliative radiotherapy for bone pain relief.

          -  Any other malignancies within the last 5 years before study entry

          -  Major surgery ≤ 2 weeks prior to study entry or who have not recovered from side
             effects of such therapy

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>51000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2014</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma lung cancer,squamous cell lung carcinoma, NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceritinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

